1. Home
  2. CHNR vs INDP Comparison

CHNR vs INDP Comparison

Compare CHNR & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo China Natural Resources Inc.

CHNR

China Natural Resources Inc.

HOLD

Current Price

$3.94

Market Cap

5.3M

ML Signal

HOLD

Logo Indaptus Therapeutics Inc.

INDP

Indaptus Therapeutics Inc.

HOLD

Current Price

$3.11

Market Cap

5.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CHNR
INDP
Founded
N/A
2000
Country
China
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.3M
5.2M
IPO Year
1996
2021

Fundamental Metrics

Financial Performance
Metric
CHNR
INDP
Price
$3.94
$3.11
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
45.1K
2.6M
Earning Date
05-15-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.16
$0.92
52 Week High
$8.20
$13.24

Technical Indicators

Market Signals
Indicator
CHNR
INDP
Relative Strength Index (RSI) 43.45 51.06
Support Level $3.35 $2.43
Resistance Level $4.12 $3.24
Average True Range (ATR) 0.30 0.56
MACD -0.03 -0.11
Stochastic Oscillator 23.73 13.85

Price Performance

Historical Comparison
CHNR
INDP

About CHNR China Natural Resources Inc.

China Natural Resources Inc is engaged in exploration for lead, silver, and other metals in the Inner Mongolia Autonomous Region of the PRC and exploration of attractive opportunities in other sectors. The company has a single operating segment: exploration and mining.

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.

Share on Social Networks: